retatrutide clinical trials efficacy safety Retatrutide, an experimental weight-loss drug, has not been approved by Retatrutide 2026: 28.7% Weight Loss

*Based on manufacturer trials studying the highest doses of oral and injectable Wegovy in non-diabetics with obesity, or with overweight plus a weight-related medical condition, when paired with diet and exercise changes (vs ~2% with diet and exercise alone)

Enjoy a high-protein, healthy-fat, and fibre-filled breakfast to start your day

For your clinic, the rules are simple: Never market compounded product as equivalent to, or the same as, a branded FDA-approved drug

Res., vol

Together, these clinically studied ingredients work to support strength, power, lean muscle development, endurance, workout capacity, and recovery while helping reduce muscle breakdown and fatigue

Preclinical data indicated that tirzepatide exhibited an affinity for GIPR equivalent to GIP binding, while its affinity for GLP-1R was approximately five times weaker compared to GLP-1 (63)